Current Status and the Need for CFTR Modulator Therapy in Cystic Fibrosis Patients in Mainland China: A Case Report and Literature Review
Pediatric Pulmonology · 2026
DOI: 10.1002/ppul.71590 ↗At a glance
Fallbericht in Pediatric Pulmonology, 2026. Written by Yuxiao Sun and 8 co-authors. Institution: Department of Pediatrics, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. Major MEDLINE topics: Aminophenols, Benzodioxoles, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator. Cited 1 times so far (Crossref); 52 references. Funded by: Zhejiang University, Jilin Provincial Key Laboratory of Biotherapy, Scientific Research Project of Education Department of Jilin Province.
Abstract (original language)
Background
Cystic fibrosis (CF) is a life‐threatening genetic disorder characterized by dysfunctional mucus production, leading to severe respiratory and digestive complications. CF transmembrane conductance regulator (CFTR) modulators are highly effective targeted therapies for CF; however, they are not yet available in mainland China, resulting in no published reports on their use in Chinese CF patients.
Objective
To report a case of CF patient with compound heterozygous CFTR mutations (c.2909G〉A/c.2491‐2A〉G) treated withelexacaftor/tezacaftor/ivacaftor (ETI) in China and summarize the diagnosis and treatment status based on a literature review, exploring the potential efficacy of CFTR modulators in the Chinese population.
Methods
Case Report: Clinical data and treatment response of a CF patient receiving ETI were analyzed. Literature Review: PubMed, CNKI, and Wanfang were searched (Jan 2010‐Aug 2025) to identify CF cases reported in China. A total of 71 cases were included for analysis of diagnosis, treatment, and outcomes.
Results
Case Outcome: The patient showed significant clinical improvement within 2 weeks after ETI initiation. Literature Analysis: The 71 cases demonstrated heterogeneity in diagnosis and treatment, with most relying on supportive therapies and lacking gene‐targeted interventions. Status Summary: CF diagnosis rates are low in China, genetic testing is insufficient, and CFTR modulator accessibility is limited.
Conclusion
This study presents the first report of CFTR modulator efficacy in a Chinese patient, indicating potential treatment benefits. It underscores the urgent need to improve CF awareness, establish a CF genetic mutation database, and expedite CFTR modulator approval/access to promote personalized treatment and outcomes.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pediatrics, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
ORCID profiles: Junbao Du, Ziwei Zhang, Hang Cheng
Funding
- Zhejiang University
- Jilin Provincial Key Laboratory of Biotherapy
- Scientific Research Project of Education Department of Jilin Province
Cite
APA
Sun, Y., Du, J., Gong, L., Wang, J., Zhang, J., Xu, Y., Wang, L., Zhang, Z., & Cheng, H. (2026). Current Status and the Need for CFTR Modulator Therapy in Cystic Fibrosis Patients in Mainland China: A Case Report and Literature Review. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71590
Vancouver
Sun Y, Du J, Gong L, Wang J, Zhang J, Xu Y, et al. Current Status and the Need for CFTR Modulator Therapy in Cystic Fibrosis Patients in Mainland China: A Case Report and Literature Review. Pediatric Pulmonology. 2026. doi:10.1002/ppul.71590
BibTeX
@article{Sun2026,
author = {Sun, Yuxiao and Du, Junbao and Gong, Lifen and Wang, Jialiang and Zhang, Jing and Xu, Yaqin and Wang, Lei and Zhang, Ziwei and Cheng, Hang},
title = {Current Status and the Need for CFTR Modulator Therapy in Cystic Fibrosis Patients in Mainland China: A Case Report and Literature Review},
journal = {Pediatric Pulmonology},
year = {2026},
doi = {10.1002/ppul.71590}
}
EUVIMED